Crinetics Pharmaceuticals, Inc. (CRNX) earnings
CRNX earnings moved a median of -1.37% by the close. Quarterly and annual CRNX reports and results, each read against the price at its own news timestamp. Back to the CRNX overview →
29 measured CRNX earnings events.
Where these CRNX earnings landedvs 29 measured CRNX earnings reactions
| Middle 50% of CRNX earnings reactions | -3.17% to +0.12% |
|---|---|
| Median reaction (to close) | -1.37% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 CRNX earnings events with a measured close landed between -3.17% and +0.12%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +0.10% | +0.12% | |
| Form 10-Q Crinetics Pharmaceutical For: Jun 30 | SEC filing · Form 10-Q | +0.10% | +0.12% | |
| Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 | Press release | -0.32% | +3.17% | |
| Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -8.50% | -12.98% | |
| Form 10-Q Crinetics Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | -8.50% | -12.98% | |
| Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | +0.27% | +0.13% | |
| Form 10-K Crinetics Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | -1.64% | -8.91% | |
| Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -0.62% | -0.15% | |
| Form 10-Q Crinetics Pharmaceutical For: Sep 30 | SEC filing · Form 10-Q | -0.62% | -0.15% | |
| Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | -0.69% | +1.65% | |
| Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -1.77% | -3.17% | |
| Form 10-Q Crinetics Pharmaceutical For: Jun 30 | SEC filing · Form 10-Q | -1.77% | -3.17% | |
| Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 | Press release | +0.66% | +1.01% | |
| Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.06% | -7.81% | |
| Form 10-Q Crinetics Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | +0.06% | -7.81% | |
| Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | Press release | +1.64% | +8.70% | |
| Form 10-K Crinetics Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | +1.50% | +5.42% | |
| Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -0.60% | -1.80% | |
| Form 10-Q Crinetics Pharmaceutical For: Sep 30 | SEC filing · Form 10-Q | -0.60% | -1.80% | |
| Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 | Press release | -0.98% | +0.99% | |
| Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +2.91% | -1.37% | |
| Form 10-Q Crinetics Pharmaceutical For: Jun 30 | SEC filing · Form 10-Q | +2.91% | -1.37% | |
| Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 | Press release | +0.25% | -0.53% | |
| Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +1.04% | -2.89% | |
| Form 10-Q Crinetics Pharmaceutical For: Mar 31 | SEC filing · Form 10-Q | +1.04% | -2.89% | |
| Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 | Press release | +1.62% | -0.67% | |
| Form 10-K Crinetics Pharmaceutical For: Dec 31 | SEC filing · Form 10-K | -1.59% | -9.20% | |
| Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | -1.01% | -2.20% | |
| Form 10-Q Crinetics Pharmaceutical For: Sep 30 | SEC filing · Form 10-Q | -1.01% | -2.20% |
Keep exploring
More CRNX: analyst actions → · SEC filings → · CRNX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ResMed Inc. (RMD) | 485 | -0.08% | 44% |
| Auris Medical Holding AG (EARS) | 484 | -0.75% | 35% |
| Medtronic plc. Ordinary Shares (MDT) | 481 | -0.06% | 45% |
| Alkermes plc - Ordinary Shares (ALKS) | 480 | -0.03% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.